These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 33143043)
1. Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update. Dorairaj V; Sulaiman SA; Abu N; Abdul Murad NA Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33143043 [TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells. Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191 [TBL] [Abstract][Full Text] [Related]
3. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951 [TBL] [Abstract][Full Text] [Related]
4. Lipotoxic hepatocyte derived LIMA1 enriched small extracellular vesicles promote hepatic stellate cells activation via inhibiting mitophagy. Li S; Yang F; Cheng F; Zhu L; Yan Y Cell Mol Biol Lett; 2024 May; 29(1):82. PubMed ID: 38822260 [TBL] [Abstract][Full Text] [Related]
5. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis. Gao H; Jin Z; Bandyopadhyay G; Wang G; Zhang D; Rocha KCE; Liu X; Zhao H; Kisseleva T; Brenner DA; Karin M; Ying W Cell Metab; 2022 Aug; 34(8):1201-1213.e5. PubMed ID: 35921818 [TBL] [Abstract][Full Text] [Related]
6. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1. Jiang F; Chen Q; Wang W; Ling Y; Yan Y; Xia P J Hepatol; 2020 Jan; 72(1):156-166. PubMed ID: 31568800 [TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets. Eguchi A; Iwasa M; Nakagawa H Liver Int; 2023 Feb; 43(2):292-298. PubMed ID: 36462157 [TBL] [Abstract][Full Text] [Related]
10. IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis. Dasgupta D; Nakao Y; Mauer AS; Thompson JM; Sehrawat TS; Liao CY; Krishnan A; Lucien F; Guo Q; Liu M; Xue F; Fukushima M; Katsumi T; Bansal A; Pandey MK; Maiers JL; DeGrado T; Ibrahim SH; Revzin A; Pavelko KD; Barry MA; Kaufman RJ; Malhi H Gastroenterology; 2020 Oct; 159(4):1487-1503.e17. PubMed ID: 32574624 [TBL] [Abstract][Full Text] [Related]
11. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease. Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease. Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Schwabe RF; Tabas I; Pajvani UB Gastroenterology; 2020 May; 158(7):1913-1928. PubMed ID: 32044315 [TBL] [Abstract][Full Text] [Related]
15. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis. Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086 [TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162 [TBL] [Abstract][Full Text] [Related]
17. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease. Kimura T; Singh S; Tanaka N; Umemura T Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271 [TBL] [Abstract][Full Text] [Related]
18. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228 [TBL] [Abstract][Full Text] [Related]
19. Aflatoxin B Yang L; Gao YL; Jiang S; Qian B; Che L; Wu JS; Du ZB; Wang MZ; Yang Y; Lin YC; Liu G; Lin ZN Ecotoxicol Environ Saf; 2024 Jun; 277():116363. PubMed ID: 38663190 [TBL] [Abstract][Full Text] [Related]
20. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]